Network
General information
| Name | Danubian Biobank Consortium |
|---|---|
| Acronym | DBC |
| Last update | 09/22/2009 |
Principal investigators
|
Oswald Wagner (Prof. Dr.)
|
Medical University Vienna |
|
Michael Brainin (Prof. Dr.)
|
Danube University Krems |
|
Wolfgang Koenig (Prof. Dr.)
|
University of Ulm |
|
Iwar Klimes (Prof. Dr.)
|
Academy of Science, Institute of Experimental Endocrinology |
|
Thomas Meitinger (Prof. Dr.)
|
GSF-National Research Centre for Environment and Health |
|
György Keri (Prof. Dr.)
|
Semmelweis University Budapest |
|
Gerd Schmitz (Prof. Dr.)
|
University Hospital Regensburg |
|
Vita Dolzan (Prof. Dr.)
|
University of Ljubljana |
|
Florian Kronenberg (Prof. Dr.)
|
Innsbruck Medical University |
|
Jaroslav A. Hubacek (Dr.)
|
Institute for Clinical and Experimental Medicine |
Contact
|
Gerd Schmitz (Prof. Dr.)
|
Institute for Clinical Chemistry, University Hospital Regensburg
Regensburgv 92053 Phone: +49 941 944 6201 Email: gerd.schmitz@klinik.uni-regensburg.de 
|
Website
Background
Aging disorders related to vascular medicine and metabolic disease are of major impact for teh European health care systems. The fastest growing segment in the European population is over 65, a group that utilizes three to five times more health care services than younger people. Despite the major progress in reducing death rates from heart disease and stroke, their impact on the health care system has dramatically increased in the past decades. Risk factors such as diabetes have increased significantly, even for younger people.
Therefore, a comprehensive public health system strategy must address these challenges. An important step in this direction is the identification and validation of new biomarkers and risk factors in population studies. Scientific discoveries, along with new technological capabilities, willl help to find and validate the specific targets, and will enable large clinical trials on new medications, along with identification of drug-dug interactions and adverse drug reactions. The introduction of the new health card in some European countries will facilitate the acquisition of precise data. It allows rapid access to exact diagnoses, lab and clinical data, and, moreover, records medication thereby allowing a more efficient identification of adverse drug reactions.
A key element in the process towards good practice-based personalized medicineis the establishment of Total-Quality-Management (TQM)-based and high-throughput-system (HTS)-based biobanks. This implies the establishment of large DNA, serum, plasma and cell/tissue/RNA/protein banks concomitantly with the development of a robotics- and IT-based infrastructure to support data integration, including patiet information as electronic patient records, in vitro as well as in vivo diagnostic data, genealogical records and the algorithms and tools required for biometric analysis. No single individual, institution or university alone can meet these challenges of information-based biomedecine. Thus, formation of regional networks combined with excellence in scientific expertise will be of outstanding importance.
Objectives
The Danubian Biobank Consortium aims to establish a "Danubian Biobank foundation for public utility in molecular medicine of aging disorders" connecting universities, associated teaching hospitals, primary prevention programs, and endpoint-related rehabilitation clinics along the Danube river and in neighbouring regions. The projectwill also integrate disease-specific patient organizations and self-care groups. The scientific network will address the field of non-cancer aging-disorders focusing on diabetes-related endpoints, including vascular disease, metabolic disease, and neurodegenerative disorders. Task forces will be constituted for the relevant topics of the biobank project including patient recruitment, sample and data management, public health, E-Health, epidemiology and genetics, enabling technologies, and research strategies. The project aims to select the most relevant and promising scientific targets utilizing the core competences developed in the individual partner institutions.
Member organizations
| Design of the member studies | Case-control |
|---|
Members
- Danubian Biobank Consortium [DBC]
- Regensburg Diabetes Endpoint Prediction and Prevention Study (REDEPPS)
- Vienna Health Study
Associated network
